Licensed Fields of Use. (a) Adjuvanted or non-adjuvanted vaccines for the prevention, cure, amelioration or treatment of respiratory syncytial virus (RSV) infection in humans, for administration alone or in combination with one or more other vaccines. For the sake of clarity, such RSV vaccines as set forth in the Licensed Patent Rights are limited to those that combine Licensed Patent Rights with Licensee’s proprietary protein-based nanoparticle technology and specifically excludes nucleic acid-based vaccines.
Licensed Fields of Use. (a) Practice of inventions claimed in Licensed Patent Rights for development, manufacture and commercialization of therapies for prostatic diseases (including but not limited to prostate cancer)
Licensed Fields of Use. (a) development and use of Licensed Patent Rights and Materials in combination with Licensee’s proprietary technology for the creation of a preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccine primes and/or boosters against -“SARS-CoV-2.”
Licensed Fields of Use. (a) Treatment and prevention of medical conditions affecting humans
Licensed Fields of Use. (a) Non-clinical development and non-clinical use of Licensed Patent Rights in combination with Licensee’s proprietary technology for the creation of a therapeutic Ebola-Zaire vaccine or booster that expresses Ebola-Zaire surface glycoprotein (GP) antigen cloned into a first insertion site and Ebola-Zaire VP40 matrix protein antigen cloned into a second insertion site;
Licensed Fields of Use. (a) The use of the Licensed Patent Rights to develop, manufacture, and sale autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma. Tumor infiltrating lymphocytes (TIL) are a subset of T lymphocytes (T cells) that migrate and are located within a tumor site. TIL isolated from these tumor sites exhibit natural anti-tumor activity without genetic modifications. For the avoidance of doubt, cell therapy products involving genetically modified TIL or TIL isolated by cancer-specific mutations are excluded from the Licensed Fields of Use, unless the cell therapy products are a combination of TIL therapy with the Licensee’s proprietary technologies or the Licensee’s in-licensed technologies.
Licensed Fields of Use. (a)The development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, as FDA approved drugs, for the treatment of Chronic Traumatic Encephalopathy (CTE) in humans.
Licensed Fields of Use. 1.4.1 Market related to the Broadcast industry.
Licensed Fields of Use. Co-Exclusive
Licensed Fields of Use. Licensed Fields of Use means the defined industry and/or markets in/on which the Licensee is authorized to sell Licensed Products.
